Thank you for your continued interest in Wegovy®.  As we have communicated, requests for Wegovy® since this medicine became available last summer have been unlike anything we had seen before, resulting in supply shortages. This was further complicated in December 2021, when we learned that the manufacturer Novo Nordisk contracts with to fill Wegovy® pens had temporarily stopped manufacturing due to issues related to Good Manufacturing Practices. 

We are doing everything we can to get Wegovy® supply replenished – and are making progress. We commit to continuing to share updates here to make sure you have the latest information:

  • For people who are ready to begin treatment or have recently started on their treatment with Wegovy®, it’s key to note we are still expecting Wegovy® supply constraints at the 0.25 mg, 0.5 mg and 1.0 mg strengths during the first half of 2022, so you may have difficulty getting your prescription of these three doses filled. This is an important consideration that may impact your treatment plan. We encourage you to speak to your healthcare provider about the weight management approach that is best for you.
  • If you are currently looking to fill your prescription for Wegovy® 1.7 mg or 2.4 mg, we are pleased to share that these dose strengths were recently shipped and are available to pharmacies across the country. This means that you should be able to continue with your treatment plan now. However, local retail pharmacies may continue to experience delays from time to time when ordering your 1.7 mg or 2.4 mg prescription strengths. That’s why we encourage you to contact your local pharmacy at least one week earlier than you normally would to check that they will be able to fill your prescription. 

We take our responsibility to you and the healthcare community very seriously.

  • We have been working around the clock with the contract manufacturer and can share they are making good progress in terms of getting production up and running again.
  • In addition, we have put plans in place to significantly expand our own Novo Nordisk Wegovy® manufacturing.
  • We have also paused advertising to avoid creating additional demand for the medicine until we have sufficient supply to ensure that people who have been prescribed Wegovy® can escalate through each of the five dose strengths.

Currently, we expect all Wegovy® doses to be fully available by the second half of 2022. We are confident that we will overcome this temporary setback. Thank you for your continued patience.

We are here to help and are ready to answer your questions at 1-833-4-WEGOVY (1-833-493-4689) from 9 AM to 6 PM Eastern Monday through Friday – and select option 0 for more support.

Please see below for important information, and don’t hesitate to call 1-833-4-WEGOVY (1-833-493-4689) and select option 0 for more support. You are our number one priority and we’re here to help.

Please click here for the Prescribing Information and Medication Guide.

We take our responsibility to you and the healthcare community very seriously, and sincerely apologize for any disruption in your treatment plan. The decision to stop or to continue taking Wegovy® should be made between you and your healthcare provider with a clear understanding of the supply situation. The Wegovy® 1.7 mg dose strength and the full dose of 2.4 mg were recently shipped and are available to pharmacies across the country. This means that you should be able to continue with your treatment plan now. However, local retail pharmacies may continue to experience delays from time to time when ordering your 1.7 mg or 2.4 mg prescription strengths. That’s why we encourage you to contact your local pharmacy at least one week earlier than you normally would to check that they will be able to fill your prescription. 

For people who are ready to begin treatment or have recently started on their weight loss journey with Wegovy®, it is important to consider that we are still expecting supply constraints on several Wegovy® dose strengths (0.25 mg, 0.5 mg and 1.0 mg).  If you need those doses, you may experience difficulty in getting your prescription filled in the coming months. We currently expect the 0.25 mg, 0.5 mg and 1.0 mg Wegovy® strengths to be fully available in the second half of 2022.

We advise you to work with your healthcare provider to determine the best approach for your treatment plan in consideration of this supply situation. Alternative FDA-approved medications for chronic weight management are available.

There are five dose strengths of Wegovy® – the first four increase in a stepwise manner (starting with 0.25 mg, then 0.5 mg, 1.0 mg and 1.7 mg) until the fifth, full dose (2.4 mg). Thank you for your continued interest in Wegovy®. Know we are doing everything we can to overcome the current supply constraints.

This situation will continue to impact the first three doses – 0.25 mg, 0.5 mg and 1.0 mg – over the coming months. The Wegovy® 1.7 mg strength and the full 2.4 mg dose were recently shipped and are available to pharmacies across the country. You should be able to continue with your treatment plan now. However, local retail pharmacies may continue to experience delays from time to time when ordering your 1.7 mg or 2.4 mg prescription strengths. That’s why we encourage you to contact your local pharmacy at least one week earlier than you normally would to check that they will be able to fill your prescription. 

We take our responsibility to you and the healthcare community very seriously, and sincerely apologize for any disruption in your treatment plan.

For more information about the Wegovy® dosing schedule, click here for the Prescribing Information and Medication Guide

This issue only impacts Wegovy® and does not affect other Novo Nordisk products in the US.

The current supply issue only affects Wegovy®. Supply of Saxenda® (liraglutide) injection 3 mg, another weight management prescription medicine made by Novo Nordisk, will not be impacted. Please speak with your healthcare provider to discuss your treatment options. Thank you for your continued patience as we work to overcome this temporary setback.

No. There is no information to indicate there is a product safety issue. However, we are still expecting supply constraints on the Wegovy® 0.25 mg, 0.5 mg and 1.0 mg dose strengths, which is an important consideration that may impact your treatment plan. We sincerely apologize for any disruption in your treatment plan and we want you to know this is a top priority for us.

Current Good Manufacturing Practices are industry standards put in place to assure proper design, monitoring and control of manufacturing processes and facilities.

Although Wegovy ® and Ozempic® both contain semaglutide, they are different products with different indications, dosages, titration schedules, etc. The products are not interchangeable. Alternative FDA-approved medications for chronic weight management are available. We advise you to speak with your healthcare provider to discuss your treatment options. 

We are working closely with the contract manufacturer and can share they are making good progress in terms of getting production up and running again. We have also increased production at another facility and have put plans in place to significantly expand our own Novo Nordisk Wegovy® manufacturing.

The demand for Wegovy® reinforces the unmet need and has strengthened our promise to not only develop innovative medicines but to partner and advocate to change how obesity is understood, diagnosed and treated.

Yes, if you have been prescribed Wegovy® and you have commercial insurance, and activated your introductory offer prior to December 31, 2021, the offer will continue to be honored for up to six (6), 28-day fills (1 box) of Wegovy® prior to June 30, 2022. After the sixth fill, or June 30, 2022, you will automatically be enrolled in the standard Wegovy® Savings Card for ongoing support. Ongoing support enables many individuals with coverage for Wegovy® to pay as little as $25 each month. However, while those without coverage can save up to $500 per 28-day supply of this medicine, they can expect an out-of-pocket cost of $800 or more. Please refer to the Terms & Conditions of your savings card for more information.

Please call 1-833-4-WEGOVY (1-833-493-4689) and select option 0.

Let us know! Please rate your experience with this page. *

{{crossValidationError['Was this page helpful'].crossValidationErrorMessage}}

If you have additional comments or would like to provide feedback on what other information would be helpful to you, please contact our Customer Care Center at 1-800-727-6500 or submit online. We will be reviewing that information on an ongoing basis and making periodic updates to this page. Please know that we take our responsibility to support you in this journey very seriously and are addressing this issue as a top priority. Thank you for your patience as we work to resolve this issue – which we will.

Your Career Guide